HOUSTON - FibroBiologics, a biotechnology firm specializing in cell therapy and regenerative medicine, has announced the issuance of three new patents by the United States Patent Office (USPTO). These patents further expand the company's significant portfolio, which includes over 150 issued and pending patents globally.
The patents are centered around innovative medical treatments using fibroblasts, a type of cell integral to the healing process. Patent 11,717,596 focuses on methods and compositions for repairing cartilage using an in vivo bioreactor. Patent 11,732,239 addresses the treatment of disc degenerative disease and stimulation of proteoglycan synthesis by fibroblast conditioned media. The third patent, 11,819,555, pertains to gene therapy for the regeneration of chondrocytes or cartilage-type cells.
Pete O'Heeron, CEO of FibroBiologics, stated that these patents validate the uniqueness of their potential treatments and processes. With the United States being the primary market for the company's product candidates, the addition of these patents is seen as a strategic move to protect their technology and intellectual property.
The company's pipeline includes treatments for various chronic diseases, such as disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics aims to represent the next generation of medical advancement in cell therapy.
This announcement is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.